CLINICAL_TRIALS ClinicalTrials.gov record update

Use of cSVF For Residual Lung Damage (COPD/Fibrotic Lung Disease After Symptomatic COVID-19 Infection For Residual Pulmonary Injury or Post-Adult Respiratory Distress Syndrome Following Viral (SARS-Co-2) Infection

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT04326036
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:39:18.683336+00:00
Published At: 2023-02-22T00:00:00+00:00
Record Updated At: 2023-02-22
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Pulmonary Alveolar Proteinosis", "COPD", "Idiopathic Pulmonary Fibrosis", "Viral Pneumonia", "Coronavirus Infection", "Interstitial Lung Disease"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2023-02-22"
protocolSection.identificationModule.nctId: "NCT04326036"
protocolSection.identificationModule.officialTitle: "Use of cSVF For Residual Lung Damage (COPD/Fibrotic Lung Disease After Symptomatic COVID-19 Infection For Residual Pulmonary Injury or Post-Adult Respiratory Distress Syndrome Following Viral (SARS-Co-2) Infection"
protocolSection.statusModule.overallStatus: "UNKNOWN"
protocolSection.designModule.phases: ["EARLY_PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.